Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Mallinckrodt
Medtronic
AstraZeneca
Dow

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR VTP-194204


✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for VTP-194204

Trial ID Title Status Sponsor Phase Summary
NCT00305929 ↗ Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure Completed STEBA France Phase 2 This is a multi-centre, phase II, open-label, 12-month clinical trial for patients previously treated with WST09 (Tookad) who have positive prostate biopsies for cancer. The study aims at delivering a second WST09 treatment for the purpose of eradicating the localized prostate cancer.
NCT00312442 ↗ Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy Terminated STEBA France Phase 2/Phase 3 The aim of this clinical trial is to evaluate the efficacy and safety of the WST09-mediated vascular-targeted photodynamic therapy (VTP) in patients with localized prostate cancer recurrent after external radiation therapy or temporary (High Dose Rate, or HDR) brachytherapy.
NCT00707356 ↗ Study of WST11 in Patients With Localized Prostate Cancer Completed Steba Biotech S.A. Phase 2 The aim of this clinical study is to determine the optimal treatment conditions to achieve prostate cancer tumor ablation and to assess the effects of WST11 mediated VTP treatment in patients with localized prostate cancer. The secondary objectives is to evaluate safety and quality of life ; to assess the pharmacokinetic parameters and to model the relationship between concentration and effects; and to assess the effects, the safety and quality of life of a second WST11 VTP treatment in patients with persistent or recurrent localized prostate cancer after a first VTP;
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for VTP-194204

Condition Name

Condition Name for
Intervention Trials
Prostate Cancer 7
Psoriasis 2
Localized Prostate Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Prostatic Neoplasms 10
Psoriasis 2
Erectile Dysfunction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for VTP-194204

Trials by Country

Trials by Country for
Location Trials
United States 26
Canada 6
France 5
United Kingdom 4
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
New York 7
North Carolina 2
New Jersey 2
Texas 2
South Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for VTP-194204

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 1
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 10
Terminated 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VTP-194204

Sponsor Name

Sponsor Name for
Sponsor Trials
Steba Biotech S.A. 12
Vitae Pharmaceuticals, Inc. 3
Vitae Pharmaceuticals Inc., an Allergan affiliate 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 18
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Baxter
Colorcon
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.